Overview

Use Misoprostol to Optimize Prevention of Cervical Cancer

Status:
RECRUITING
Trial end date:
2027-11-04
Target enrollment:
Participant gender:
Summary
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Phase:
NA
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
Cameroon Baptist Convention Health Core
Treatments:
Misoprostol